NetScientific PLC (LON:NSCI) said portfolio firm and circulating tumor cell group Vortex Biosciences has hired Deborah Neff as a non-executive director.
She will play a critical role providing strategic oversight, as its circulating tumor cell enrichment system, the VTX-1, is progressed towards commercialisation, Netscientific said.
Neff has served in a number of leadership positions in healthcare companies, including a 15-year career at Becton Dickinson & Co in executive management positions,
The planned commercial launch of the VTX-1 system is planned for the first quarter of 2017.
It is a fully automated benchtop system for capturing intact circulating tumor cells (CTCs) directly from whole blood samples without any preprocessing steps.
CTCs, shed by cancer tumors, can potentially reveal disease recurrence or disease progression earlier than imaging and more reliably compared with standard biomarkers.